お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
955008

インドのCOVID-19感染拡大対策製品(COVID-19用医薬品市場、COVID-19用ワクチン市場、個人用保護具 (PPE)、自己採取用スワブ、COVID-19用人工知能 (AI)、個人用防具、遠隔放射線診断、眼球保護具など)市場:2024年まで

India COVID-19 Pandemic Mitigation Products (COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, and More) Market to 2024

出版日: | 発行: Homeland Security Research Corporation (HSRC) | ページ情報: 英文 420 Pages; 220 Tables & Figures | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
インドのCOVID-19感染拡大対策製品(COVID-19用医薬品市場、COVID-19用ワクチン市場、個人用保護具 (PPE)、自己採取用スワブ、COVID-19用人工知能 (AI)、個人用防具、遠隔放射線診断、眼球保護具など)市場:2024年まで
出版日: 2020年08月26日
発行: Homeland Security Research Corporation (HSRC)
ページ情報: 英文 420 Pages; 220 Tables & Figures
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

インドの新型コロナウイルス感染症 (COVID-19) 感染拡大向け対策製品の市場規模は、2020年~2024年の累計で670~910億米ドルに達する見通しです (年度・予測シナリオに因ります)。

インド国内のCOVID-19感染者数は、2020年末までに400万人以上に達し、更に2021年には2000万人以上に達すると見込まれています。感染拡大による経済的・社会的混乱を防止すべく、多額の資金を投じてワクチン開発や医療対策用人工知能 (AI)/機械学習 (ML) の開発が進められています。

当レポートでは、インド国内のCOVID-19感染拡大対策製品の市場について分析し、全体的な市場規模 (処置件数) の動向見通しや、主要製品/サービス別・エンドユーザー別の詳細動向、シナリオ別の将来予測、業界関係者が今後解決すべき課題、といった情報を取りまとめてお届けいたします。

当レポートの予測シナリオ

  • 1. 楽観的シナリオ - ワクチンの大量摂取が2021年7月までに開始される場合
  • 2. 慎重なシナリオ - 2025年まで集団予防接種が利用できない場合

A. 当レポートの分析内容

  • インドのCOVID-19感染拡大対策製品の市場規模の予測値 (2020年~2024年)
  • 最も求心力の強いビジネスチャンス
  • 顧客がソリューションやサービスを購入する契機
  • インドのCOVID-19感染拡大対策製品の市場動向
  • 市場の浸透・成長に際しての課題

B. 主要製品・サービス別分析 (全29項目):

  • 1. COVID-19用ワクチン
  • 2. COVID-19用薬剤
  • 3. PCR検査装置・ソフトウェア
  • 4. PCR検査用試薬・消耗品
  • 5. 鼻用・口用綿棒
  • 6. 自己採取式PCR検査キット
  • 7. 血清検査キット
  • 8. スタンドオフ温度計
  • 9. X線・CT・超音波処置
  • 10. 廃水検査
  • 11. PACS (医療用画像管理システム)/テレラジオロジー (遠隔放射線診断)
  • 12. 医療用PPEガウン
  • 13. 医療用手袋
  • 14. 医療用フェイスマスク
  • 15. 医療用フェイスシールド
  • 16. 医療用眼球保護具
  • 17. 滅菌装置・消耗品
  • 18. 人工知能 (AI)、ビッグデータ、機械学習 (ML)
  • 19. 在宅治療用IT
  • 20. 接触追跡システム・サービス
  • 21. 電子医療 (eヘルス)
  • 22. 他のパンデミック関連ICT
  • 23. COVID-19用ホームケア(装置、ソフトウェア、サービス)
  • 24. 人工呼吸器
  • 25. 災害対応病院/ICU
  • 26. その他の集中治療室 (ICU)
  • 27. パンデミック関連の製造工場
  • 28. 研究開発 (R&D) 用装置・消耗品
  • 29. その他の製品・サービス

エンドユーザー市場別分析 (全6項目):

  • 1. 病院・救急病院
  • 2. 臨床検査室
  • 3. 診療所
  • 4. 救急医療サービス(EMS)
  • 5. 在宅介護・介護施設
  • 6. 研究機関

収入源別の分析 (全4種類):

  • 1. 製品販売
  • 2. 訓練サービス
  • 3. 計画・コンサルティング
  • 4. 整備・更新

C. 市場の部門別分析:分析フレームワークの詳細

  • 1. 市場の促進・抑制要因
  • 2. ビジネス機会
  • 3. SWOT分析
  • 4. 製品別・サービス別の競争力分析
    • 1. 市場参入障壁
    • 2. サプライヤーの交渉力
    • 3. バイヤーの交渉力
    • 4. 代替製品に対する障壁
  • 5. 事業環境
  • 6. 市場の動向見通し:サブ市場別 (全3種類、2020年~2024年)

D. 主要企業の最新動向・市場データ (全37社分)

    企業のプロファイル、近年の年間収益額、COVID-19対策活動・製品、連絡先情報など

E. COVID-19感染拡大対策コミュニティの情報源 (計2300件以上)

F. 本文中で言及されたベンダー (計450件以上)

Moderna、IBM、3M Company、Philips NV、Johnson & Johnson、Roche、Nvidia Corporation、Thermo Fisher Scientific、Siemens、Toshiba、Google、Samsung Electronics Co、GE Healthcare、Medtronic、MedWhat、MedyMatch、Merck、Metabiota、Micron Technology、Infermedica、Infervision、Inovio Pharmaceuticals、Microsoft Corporation、Mindshare Medical、Morpheo、Pfizer、Philips NV、Maxim Biotech、Honeywell Safety Products、Philips Healthcare、Siemens、Recursion Pharmaceuticals、Fujifilm Holdings Corporation、3Scan、Abbott 、AbCellera、Advenio Technosys、Agfa Healthcare、Agilent Technologies、AiCure、Aindra、Allscripts Healthcare Solutions、Amara Health Analytics、Amazon 、analyticsMD、Apixio、Apple、Arterys Inc.、Atlas Wearables、Atomwise、Avalon Nutrition VITL、Babylon Health、Bay Labs、Behold.ai、benevolent.ai、BIOBEATS、BlueDot、Bollé Safety、Bullard、Buoy Health、Care Angel Wearables QorQL、Careskore、Clinithink、Cloud Pharmaceuticals、CloudMedx、CureMetrix Mental health Ginger.io、Cyrcadia、Deep 6 AI、Deep Genomics、Dell Technologies Inc.、Delta Plus Group、Desktop Genetics Virtual mate Ada Health、DreaMed Diabetes、Dupont、EaglEyeMed、Eli Lilly、Encon Safety Products、Enlitic、EnsoData、Entopsis、Envisagenics Research iCarbonX、ERB Industries Inc.、Ergodyne、Essilor of America、Flashback Technologies、Flow Health、Ford、Freenome、Frequency Therapeutics Inc.、Gateway Safety Inc.、General Motors、General Vision、Gentex Corporation、Gibco、Gilead Sciences、Globavir Biosciences、Healint、Health Fidelity、HealthNextGen、HexArmor、Hindsait、Imagen Technologies、Imagia Cybernetics、Inside DNA、InSilico Medicine、Intel Corporation、Intendu、Invitrogen、Ion Torrent、Ironwear、Jvion、Kapa Biosystems、Keen Eye Technologies、Kimberly-Clark Professional、Lexmark International Inc.、LifeGraph、Lucina Health、Lumiata、Lunit、Lytics、Magnea、Maxwell MRI、McKesson Corporation、MCR Safety、Medal、Medalogix、Medasense、MedAware、Niramai Health Analytix、Novarad Corporation、NuMedii、Numerate、Nuritas Pharma Turbine、Oncora Medical、Ovuline、PeerWell、PhysIQ、Precision Health Intelligence、Predible Health、Profility、Proscia、pulseData、Pyramex Safety、Qualaris Healthcare Solutions、Qualcomm Incorporated、Qualcomm Incorporated、Qure.Ai、Radians Inc.、Roam Analytics、RxPREDICT、Safety Optical Service Ltd、Sanofi、Saykara、Sellstrom Manufacturing Company (SureWerx)、Sense.ly、Sensory Inc.、Sigma-Aldrich Corp.、Skymind Inc.、Vir Biotechnology Inc.、VisionAid Inc.、WuXi Biologics、Xilinx Inc. など

G. 付録

  • 付録1:一般的なインフルエンザとコロナウイルスの相違点と類似点
  • 付録2:COVID-19検査
  • 付録3:略語
  • 付録4:用語集
  • 付録5:参考文献
目次

Title:
India COVID-19 Pandemic Mitigation Products
(COVID-19 Drugs Market, COVID-19 Vaccine Market, PPE, Self-collection Swabs, COVID-19 AI, Personal Protection Gear, Teleradiology, Eye Protection, CT, X-Ray, Ultrasound, COVID-19 IT, Telemedicine, PACS, Face Shields, PPE Gowns, Coronavirus Homecare, Mechanical Ventilators, Gloves, E-Health, Robotic PCR Market, Point of Care Antigen Test, PCR Reagents, Face Masks, ICU, Contact Tracing, Sterilization Systems, Point of Care Serologic Test, Polymerase Chain Reaction, Test Kits, Surge Hospitals and More) Market to 2024.

On the backdrop of the need for essential medical products and services, a new market has emerged, the COVID-19 pandemic mitigation products market. This India COVID-19 pandemic mitigation cumulative 2020-2024 market is worth $67-$91 Billion*.

(*) Market size is year and scenario dependent.

To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:

  • 1. Optimistic scenario - assumes (among other things) that mass vaccination will commence by July 2021
  • 2. Conservative scenario - assumes (among other things) that no mass vaccination will be available until July 2024

Why trust this report?

  • The team which created this report was led by ex-executives of the medical industry and bio-security experts, who wrote this report with the COVID-19 industry executives in mind
  • As the COVID-19 pandemic knowledge changes all the time, we update the report once a month
  • The team has published since 2006 36 Pandemic related reports
  • Team members exported medical systems & instrumentation to India since 1982

Bottom Line: While other COVID-19 reports are written (at best) by MBAs, this report is published by professionals for experts

According to the report:

Initially, India took the harshest measures anywhere to slow down the COVID-19 outbreak, ordering the entire 1.3 billion citizens under a countrywide lock-down. The measures were severely tough on the neediest Indians. Various restraints were relaxed in May to support the economy.

On the one hand, the United Nations and WHO have commended India's reaction to the outbreak as "Comprehensive and robust," labeling the Lockdown controls as assertive but vital for containing the pandemic. The Oxford COVID-19 Government Response Tracker noted the Indian PM's swift and stringent actions, emergency policy making, emergency investment in healthcare infrastructure, monetary stimulus, and financing in vaccine and drug development projects. It gave India a score of 100 for its strict response. On the bright side India had the capability to manage the outbreak due to its past knowledge in eradicating smallpox and polio.

On the other hand, India's officials issued well over 4,000 different rules during the two long months that they kept India's 1.3 bn citizens shut indoors. Most of this torrent of instruction was well meant. Yet many of the rules caused as much trouble as they resolved. This is most obvious regarding tens of millions of migrant workers who were left without subsistence.

India's COVID-19 pandemic mitigation products market is driven by the demand for the following:

  • India is already the third nation following the USA and Brazil when it comes to the number of reported infections.
  • India's healthcare system is already stretched, it spent $68 per capita compared to the USA's $10,000 and China's $433 per capita. Furthermore by 2019 India's healthcare funding was a meager $93 Billion compared to China's $621 Billion for a population that surpass India by just 5%.
  • The pandemic has triggered the most severe economic recession in over a century and is causing enormous damage to the Indian people's health, jobs and well-being. India's government has no choice but to prioritize reopening and accept the consequences of escalating infections.
  • We forecast that by the end of 2020 India will have more than 4 million people infected. The country's healthcare infrastructure will collapse.
  • Our (and others) most optimistic forecast is that by 2021 at least 20 million will be infected in India.
  • On the backdrop of the first on-going outbreak in the country, and the removal of the lockdown, the country's healthcare establishment invests billions to mitigate the next wave of the pandemic
  • The growing size of coronavirus related information and mounting complications of datasets, and the need saved by financial resources
  • Advanced AI and machine learning have a high demand among general practitioners and others who are not coronavirus ICU experts
  • The country's pharma and biotech companies research and development of coronavirus vaccines and medications

and demand for:

  • Low cost PCR tests.
  • Low cost Serologic Tests
  • Low cost Ventilators
  • Electronic Contact Tracing
  • Surge Hospitals
  • PPE
  • Low cost Invasive ventilators
  • New ICU units
  • Low cost COVID-19 medications
  • COVID-19 Informatics
  • Mobile X-Ray imaging services
  • Training of ICU and ER personnel
  • Pandemic related turnkey manufacturing plants
  • Strategic National Stockpile

This 420 -page market report is the most comprehensive review of the Indian COVID-19 market available today. The objective of this report is to provide today's strategic decision-makers with an expert 360-degree, time-sensitive, detailed view of this interconnected market.

The ‘ India COVID-19 Pandemic Mitigation Products Market - 2020-2024 ’ report presents a thorough market analysis of 29 products & services, 6 end user, 4 revenue source markets. Furthermore , the report provides updated extensive data of 37 key vendors.

Why Buy this India COVID-19 Pandemic Mitigation Products Market Report?

A. Questions answered in this report include:

  • What is the Indian COVID-19 Market size and what are the forecast trends during 2020-2024?
  • What are the most attractive business opportunities?
  • What drives the customers to purchase solutions and services?
  • What are the Indian COVID-19 Market trends?
  • What are the challenges to market penetration & growth?

B. Indian COVID-19 market size data is analyzed via 5 independent key perspectives. With a highly fragmented market we address the "money trail" - each dollar spent in the Indian COVID-19 market is analyzed and crosschecked via 3 orthogonal viewpoints:

By 29 Products and Services:

  • 1. COVID-19 Vaccines
  • 2. COVID-19 Drugs
  • 3. PCR Instrumentation & Software
  • 4. PCR Reagents & Consumables
  • 5. Nose & Mouth Swabs
  • 6. Self-collection PCR Test Kits
  • 7. Serologic Test Kits
  • 8. Standoff Thermometry
  • 9. X-Ray, CT & Ultrasound Procedures
  • 10. Wastewater testing
  • 11. PACS & Teleradiology
  • 12. Medical PPE Gowns
  • 13. Medical Gloves
  • 14. Medical Face Masks
  • 15. Medical Face Shields
  • 16. Medical Eye Protection
  • 17. Sterilization: Systems & Consumables
  • 18. AI, Big Data & Machine Learning
  • 19. Homecare IT
  • 20. Contact Tracing Systems & Services
  • 21. E-Health
  • 22. Other Pandemic Related ICT
  • 23. COVID-19 Homecare (Equipment, Software, Services)
  • 24. Ventilators
  • 25. Surge Capacity Hospitals & Surge ICUs
  • 26. Other Intensive Care Modalities
  • 27. Pandemic Related Manufacturing Plants
  • 28. R&D Equipment & Consumables
  • 29. Other Products & Services

By 6 End User Markets:

  • 1. Hospitals and Surge Hospitals
  • 2. Clinical Labs
  • 3. Clinics
  • 4. Emergency Medical Services (EMS)
  • 5. Homecare & Nursing Homes
  • 6. Research Bodies

By 4 Revenue Source Markets:

  • 1. Product Sales
  • 2. Training Services
  • 3. Planning & Consulting
  • 4. Maintenance & Upgrade

C. Detailed market analysis frameworks for each of the market sectors are provided, including:

  • 1. Market drivers & inhibitors
  • 2. Business opportunities
  • 3. SWOT analysis
  • 4. Competitive analysis for each of the products and services that covers:
  • 1. Barriers to Entry
  • 2. Supplier Power
  • 3. Buyer Power
  • 4. Barriers to Substitution.
  • 5. Business environment
  • 6. The 2020-2024 market size

D. The report provides an updated extensive data of the leading 37 companies

(including companies' profile, recent annual revenues, COVID-19 mitigation activities & products and contact information).

E. The report includes over 2300 links to the COVID-19 pandemic mitigation community information sources

F. The report mentions > 450 Vendors including the following:

Moderna, IBM, 3M Company, Philips NV, Johnson & Johnson, Roche, Nvidia Corporation, Thermo Fisher Scientific, Siemens, Toshiba, Google, Samsung Electronics Co, GE Healthcare, Medtronic, MedWhat, MedyMatch, Merck, Metabiota, Micron Technology, Infermedica, Infervision, Inovio Pharmaceuticals, Microsoft Corporation, Mindshare Medical, Morpheo, Pfizer, Philips NV, Maxim Biotech, Honeywell Safety Products, Philips Healthcare, Siemens, Recursion Pharmaceuticals, Fujifilm Holdings Corporation, 3Scan, Abbott , AbCellera, Advenio Technosys, Agfa Healthcare, Agilent Technologies, AiCure, Aindra, Allscripts Healthcare Solutions, Amara Health Analytics, Amazon , analyticsMD, Apixio, Apple, Arterys Inc., Atlas Wearables, Atomwise, Avalon Nutrition VITL, Babylon Health, Bay Labs, Behold.ai, benevolent.ai, BIOBEATS, BlueDot, Bollé Safety, Bullard, Buoy Health, Care Angel Wearables QorQL, Careskore, Clinithink, Cloud Pharmaceuticals, CloudMedx, CureMetrix Mental health Ginger.io, Cyrcadia, Deep 6 AI, Deep Genomics, Dell Technologies Inc., Delta Plus Group, Desktop Genetics Virtual mate Ada Health, DreaMed Diabetes, Dupont, EaglEyeMed, Eli Lilly, Encon Safety Products, Enlitic, EnsoData, Entopsis, Envisagenics Research iCarbonX, ERB Industries Inc., Ergodyne, Essilor of America, Flashback Technologies, Flow Health, Ford, Freenome, Frequency Therapeutics Inc., Gateway Safety Inc., General Motors, General Vision, Gentex Corporation, Gibco, Gilead Sciences, Globavir Biosciences, Healint, Health Fidelity, HealthNextGen, HexArmor, Hindsait, Imagen Technologies, Imagia Cybernetics, Inside DNA, InSilico Medicine, Intel Corporation, Intendu, Invitrogen, Ion Torrent, Ironwear, Jvion, Kapa Biosystems, Keen Eye Technologies, Kimberly-Clark Professional, Lexmark International Inc., LifeGraph, Lucina Health, Lumiata, Lunit, Lytics, Magnea, Maxwell MRI, McKesson Corporation, MCR Safety, Medal, Medalogix, Medasense, MedAware, Niramai Health Analytix, Novarad Corporation, NuMedii, Numerate, Nuritas Pharma Turbine, Oncora Medical, Ovuline, PeerWell, PhysIQ, Precision Health Intelligence, Predible Health, Profility, Proscia, pulseData, Pyramex Safety, Qualaris Healthcare Solutions, Qualcomm Incorporated, Qualcomm Incorporated, Qure.Ai, Radians Inc., Roam Analytics, RxPREDICT, Safety Optical Service Ltd, Sanofi, Saykara, Sellstrom Manufacturing Company (SureWerx), Sense.ly, Sensory Inc., Sigma-Aldrich Corp., Skymind Inc., Vir Biotechnology Inc., VisionAid Inc., WuXi Biologics, Xilinx Inc. and more.

G. India COVID-19 market report includes 5 appendices:

  • Appendix 1: Differences & Similarities between Common Flu and Coronavirus
  • Appendix 2: COVID-19 Tests
  • Appendix 3: Abbreviations
  • Appendix 4: Glossary
  • Appendix 5: Bibliography

COVID-19 pandemic mitigation market research team

The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen identification, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, ultrasound, electron microscopy, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.

As early as January 20, 2020 we recruited all our analysts to research the COVID-19 pandemic mitigation related products purchases. We interviewed hundreds of experts, participated in more than 95 conferences and webinars, reviewed more than 1,500 publications and interviewed executives of more than 65 pandemic related companies.

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.